¶¶Òõ¶ÌÊÓƵ

Dr. Mona Talib Obaid was recently appointed medical director for KSA at Eli Lilly and Co. She has become the first Saudi woman to hold a top leadership position in the Kingdom’s pharmaceutical sector.
Obaid received her MBBS from King Saud University in 2001. She is also board certified by the Saudi Internal Medicine Board.
Obaid completed a fellowship at the Royal College of Physicians in the UK in 2006.
She received certifications from the Canadian Board of Adult Neurology. Obaid then completed two fellowships. The first was in movement disorders from the University of Alberta, Canada, and the second in deep brain stimulation from the University of Joseph Fourier, France.
Obaid, who is a board member of the Saudi Alzheimer’s Disease Association and the Saudi Neurology Society, was a consultant neurologist at King Fahad Medical City (KFMC) in Riyadh. Moreover, she is also a scientific member on the neurology board at the Saudi Commission for Health Specialties. Obaid has also worked with the Dr. Sulaiman Al-Habib Medical Group.
In September 2020, she attended an executive women’s leadership program, called Pioneer, designed by the Healthcare Leadership Academy for senior women leaders.
Its purpose was to build and sustain the leadership and change management knowledge, skills, and behaviors necessary to support the transformation agenda facing the health sector. The program was the first of its kind in the Kingdom.
 In 2014, she was honored as the most compassionate physician at KFMC’s National Neuroscience Institute. She also received a letter of recognition for her active participation in the Saudi Parkinson Society three years later.
Obaid recently participated as a speaker at the virtual Congress 2020 of the International Parkinson and Movement Disorder Society (MDS), a professional society of clinicians and healthcare professionals.